Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Li, Heng ^a   Yu, Gan ^a   Shi, Runlin ^a   Lang, Bin ^b   Chen, Xianguo ^c   Xia, Ding ^a   Xiao, Haibing ^a   Guo, Xiaolin ^a   Guan, Wei ^a   Ye, Zhangqun ^a   Xiao, Wei ^a   Xu, Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b MACAO POLYTECHNIC INSTITUTE   (Macao)

^c ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

CD44; Chemosensitivity; miR 34a; Muscle invasive bladder cancer; Promoter hypermethylation

Indexed keywords

CISPLATIN; HERMES ANTIGEN; MICRORNA 34A; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOGENICITY; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PROMOTER REGION;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CISPLATIN; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; MICE; MICE, NUDE; MICRORNAS; PROMOTER REGIONS, GENETIC; TRANSFECTION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899147129     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-8     Document Type: Article

References (38)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009, 27:289-293. 10.1007/s00345-009-0383-3, 2694323, 19219610.
2. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA,. European Association of U [Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines]. Actas urologicas espanolas 2012, 36:449-460. European Association of U.
3. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007, 177:437-443. 10.1016/j.juro.2006.09.027, 17222605.
4. Chekulaeva M, Filipowicz W. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 2009, 21:452-460. 10.1016/j.ceb.2009.04.009, 19450959.
5. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008, 7:1-9.
6. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell cycle 2008, 7:2591-2600. 10.4161/cc.7.16.6533, 18719384.
7. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010, 70:5923-5930. 10.1158/0008-5472.CAN-10-0655, 2913706, 20570894.
8. Ji X, Wang Z, Geamanu A, Goja A, Sarkar FH, Gupta SV. Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. International journal of cancer Journal international du cancer 2012, 131:2668-2677. 10.1002/ijc.27549, 22438124.
9. Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. International journal of cancer Journal international du cancer 2012, 130:2526-2538. 10.1002/ijc.26256, 21702042.
10. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, et al. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 2012, 226:796-805. 10.1002/path.3007, 21960059.
11. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010, 16:214-218. 10.1038/nm.2090, 2826790, 20098429.
12. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134. 10.1038/nature05939, 17554337.
13. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell cycle 2007, 6:1586-1593. 10.4161/cc.6.13.4436, 17554199.
14. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752. 10.1016/j.molcel.2007.05.010, 1939978, 17540599.
15. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011, 59:671-681. 10.1016/j.eururo.2011.01.044, 21296484.
16. Ke B, Shen XD, Kamo N, Ji H, Yue S, Gao F, Busuttil RW, Kupiec-Weglinski JW. beta-catenin regulates innate and adaptive immunity in mouse liver ischemia-reperfusion injury. Hepatology 2013, 57:1203-1214. 10.1002/hep.26100, 3594407, 23081841.
17. Zhang M, Ueki S, Kimura S, Yoshida O, Castellaneta A, Ozaki KS, Demetris AJ, Ross M, Vodovotz Y, Thomson AW, et al. Roles of dendritic cells in murine hepatic warm and liver transplantation-induced cold ischemia/reperfusion injury. Hepatology 2013, 57:1585-1596. 10.1002/hep.26129, 23184590.
18. Cao Z, Mulvihill MM, Mukhopadhyay P, Xu H, Erdelyi K, Hao E, Holovac E, Hasko G, Cravatt BF, Nomura DK, Pacher P. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013, 144:808-817. e815, 10.1053/j.gastro.2012.12.028, 23295443.
19. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, Hansen TB, Jensen TI, Borre M, Orntoft TF, et al. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer 2012, 106:366-374. 10.1038/bjc.2011.520, 3261682, 22108519.
20. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007, 104:15472-15477. 10.1073/pnas.0707351104, 2000550, 17875987.
21. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010, 16:1119-1128. 10.1158/1078-0432.CCR-09-2642, 2822884, 20145172.
22. Kamo N, Ke B, Ghaffari AA, Busuttil RW, Cheng G, Kupiec-Weglinski JW. The ASC/Caspase-1/IL-1beta signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia-reperfusion injury. Hepatology 2013, 58(1):351-362. doi: 10.1002/hep.26320. Epub 2013 May 15, 10.1002/hep.26320, 23408710.
23. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011, 17:211-215. 10.1038/nm.2284, 3076220, 21240262.
24. Nace GW, Huang H, Klune JR, Eid RE, Rosborough BR, Korff S, Li S, Shapiro RA, Stolz DB, Sodhi CP, et al. Cellular specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury. Hepatology 2013, 58(1):374-387. doi: 10.1002/hep.26346. Epub 2013 May 27, 10.1002/hep.26346, 23460269.
25. Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, Winkler D, Durig J, van Oers MH, Mertens D, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009, 113:3801-3808. 10.1182/blood-2008-08-172254, 18941118.
26. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010, 17:193-199. 10.1038/cdd.2009.56, 19461653.
27. Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation-from bench to bedside. Nat Rev Gastroenterol Hepatol 2013, 10:79-89. 3577927, 23229329.
28. Yang YM, Chang JW. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Investig 2008, 26:725-733.
29. Kuncova J, Kostrouch Z, Viale M, Revoltella R, Mandys V. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197. Folia biologica 2005, 51:3-11.
30. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Chang HY, van de Rijn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009, 106:14016-14021. 10.1073/pnas.0906549106, 2720852, 19666525.
31. Choudhary S, Kalita M, Fang L, Patel K, Tian B, Zhao Y, Edeh CB, Brasier AR. Inducible TNF Receptor Associated Factor-1 Expression Couples to the Canonical to the Non-Canonical NF-kappaB pathway in TNF stimulation. J Biol Chem 2013, 288(20):14612-14623. doi: 10.1074/jbc.M113.464081. Epub 2013 Mar 29, 10.1074/jbc.M113.464081, 23543740.
32. Xiang F, Huang YS, Shi XH, Zhang Q. Mitochondrial chaperone tumour necrosis factor receptor-associated protein 1 protects cardiomyocytes from hypoxic injury by regulating mitochondrial permeability transition pore opening. FEBS J 2010, 277:1929-1938. 10.1111/j.1742-4658.2010.07615.x, 20236315.
33. Pryhuber GS, Huyck HL, Roper JM, Cornejo J, O'Reilly MA, Pierce RH, Tsitsikov EN. Acute Tumor Necrosis Factor-α-Induced Liver Injury in the Absence of Tumor Necrosis Factor Receptor-Associated Factor 1 Gene Expression. Am J Pathol 2005, 166:1637-1645. 10.1016/S0002-9440(10)62474-1, 1602417, 15920149.
34. Kim H-S, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer cell 2010, 17:41-52. 10.1016/j.ccr.2009.11.023, 3711519, 20129246.
35. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 2010, 12:662-667. 10.1016/j.cmet.2010.11.015, 21109198.
36. Yan H, Chen X, Zhang Q, Qin J, Li H, Liu C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, et al. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PloS one 2011, 6:e24397. 10.1371/journal.pone.0024397, 3174165, 21935404.
37. Beraza N, Malato Y, Sander LE, Al-Masaoudi M, Freimuth J, Riethmacher D, Gores GJ, Roskams T, Liedtke C, Trautwein C. Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. J Exp Med 2009, 206:1727-1737. 10.1084/jem.20082152, 2722179, 19635861.
38. Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y, Dahiya R. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 2011, 71:6208-6219. 10.1158/0008-5472.CAN-11-0073, 3940359, 21852381.